Advanced-DiaRem评分改善Roux-en-Y胃旁路术后1年糖尿病缓解预测
在法国回顾性队列(n=1866,含352例2型糖尿病者,RYGB术后随访1年)中开发Advanced-DiaRem评分,并在法国(n=134)和以色列(n=99)独立队列验证。在原始DiaRem基础上增加糖尿病病程和降糖药数量并修改各分类惩罚项后,Ad-DiaRem的AUC和预测准确率均优于DiaRem,并纠正了8%最初被DiaRem误分类者的分类。
要点
- Ad-DiaRem在原始DiaRem基础上增加糖尿病病程和降糖药数量两个临床变量,并修改各分类惩罚项。
- Ad-DiaRem的AUC为0.911 vs DiaRem 0.856,预测准确率为0.841 vs 0.789(p=0.03)。
- Ad-DiaRem纠正了8%最初被DiaRem误分类者的分类,并减少中间评分段个体的误分类。
核心结论
- 作者提出包含两个额外临床变量的Ad-DiaRem,作为预测RYGB术后1年糖尿病缓解的优化工具,准确性有所提高。
- 该工具可能有助于常规诊疗中考虑减重手术时对糖尿病患者进行个体化管理,最终促进精准医学。
研究设计与样本
- 使用法国回顾性队列(n=1866),其中包含352例2型糖尿病个体,RYGB术后随访1年。
- 在测试队列(n=213)中开发Ad-DiaRem,并在法国(n=134)和以色列(n=99)独立队列中检验其准确性。
主要发现
- 在原始DiaRem基础上增加两个临床变量(糖尿病病程和降糖药数量)并修改各分类惩罚项后,Ad-DiaRem预测性能改善。
- Ad-DiaRem的受试者工作特征曲线下面积和预测准确率均优于DiaRem(分别为0.911 vs 0.856和0.841 vs 0.789;p=0.03)。
- Ad-DiaRem纠正了8%最初被DiaRem误分类者的分类。
- 使用Ad-DiaRem时,中间评分段个体的误分类也减少。
- 改善的预测性能在独立队列中得到证实。
关键数值与推荐
- Ad-DiaRem的AUC为0.911,DiaRem为0.856(p=0.03)。
- Ad-DiaRem的预测准确率为0.841,DiaRem为0.789(p=0.03)。
- Ad-DiaRem纠正了8%最初被DiaRem误分类者的分类。
临床怎么用
- 作者提出Ad-DiaRem作为预测RYGB术后1年糖尿病缓解的优化工具,可能有助于常规诊疗中考虑减重手术时的个体化管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Not all people with type 2 diabetes who undergo bariatric surgery achieve diabetes remission. Thus it is critical to develop methods for predicting outcomes that are applicable for clinical practice. The DiaRem score is relevant for predicting diabetes remission post-Roux-en-Y gastric bypass (RYGB), but it is not accurate for all individuals across the entire spectrum of scores. We aimed to develop an improved scoring system for predicting diabetes remission following RYGB (the Advanced-DiaRem [Ad-DiaRem]). METHODS: We used a retrospective French cohort (n = 1866) that included 352 individuals with type 2 diabetes followed for 1 year post-RYGB. We developed the Ad-DiaRem in a test cohort (n = 213) and examined its accuracy in independent cohorts from France (n = 134) and Israel (n = 99). RESULTS: Adding two clinical variables (diabetes duration and number of glucose-lowering agents) to the original DiaRem and modifying the penalties for each category led to improved predictive performance for Ad-DiaRem. Ad-DiaRem displayed improved area under the receiver operating characteristic curve and predictive accuracy compared with DiaRem (0.911 vs 0.856 and 0.841 vs 0.789, respectively; p = 0.03); thus correcting classification for 8% of those initially misclassified with DiaRem. With Ad-DiaRem, there were also fewer misclassifications of individuals with mid-range scores. This improved predictive performance was confirmed in independent cohorts. CONCLUSIONS/INTERPRETATION: We propose the Ad-DiaRem, which includes two additional clinical variables, as an optimised tool with improved accuracy to predict diabetes remission 1 year post-RYGB. This tool might be helpful for personalised management of individuals with diabetes when considering bariatric surgery in routine care, ultimately contributing to precision medicine.
引用
- Aron-Wisnewsky J, Sokolovska N, Liu Y, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia. 2017. PMID: 28733906. doi:10.1007/s00125-017-4371-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。